NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences
NorthStrive Biosciences, a subsidiary of PMGC Holdings (ELAB), announced positive Phase III results from its AI-driven drug discovery program with partner Yuva Biosciences. Four AI-selected small-molecule candidates demonstrated statistically significant increases in ANT1 expression in primary human skeletal muscle cells, with the strongest showing up to 50% induction.
Key figures
- Drug Name
- EL-22 (lead asset context)
- Phase Of Trial
- Phase III (in vitro discovery stage)
- Ant1 induction c1
- +46%
- Ant1 induction c2
- +50%
- Ant1 induction c3
- +29%
- Ant1 induction c4
- +48%
- Validated candidates
- 4
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.